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Aims 1) To investigate whether genetic liability to attention-deficit/hyperactivity disorder (ADHD), 
indexed by polygenic risk scores for ADHD (PRS-ADHD), is associated with substance use 
disorders (SUD) in individuals with ADHD. 2) To investigate whether other individual- or family-
related risk factors for SUD could mediate or confound this association. 
Design Population-based cohort study 
Setting and participants ADHD cases in the iPSYCH sample, born in Denmark between 1981 and 
2003 (N = 13 116). Register-based information on hospital diagnoses of SUD was available until 
December 31, 2016.  
Measurements We estimated odds ratios (ORs) with 95% confidence intervals (CIs) for any SUD 
as well as for different SUD types (alcohol, cannabis, and other illicit drugs) and severities (use, 
abuse, and addiction), with effect sizes corresponding to a comparison of the highest PRS-ADHD 
decile to the lowest.  
Findings PRS-ADHD were associated with any SUD (OR = 1.30, 95% CI: 1.11-1.51). Estimates 
were similar across different types and severity levels of SUD. Other risk factors for SUD (male 
sex, age at ADHD diagnosis, comorbid conduct problems, and parental factors including SUD, 
mental disorders, and socio-economic status) were independently associated with increased risk of 
SUD. PRS-ADHD explained a minor proportion of the variance in SUD (0.2% on the liability 
scale) compared to the other risk factors. The association between PRS-ADHD and any SUD was 
slightly attenuated (OR = 1.21, 95% CI: 1.03-1.41) after adjusting for the other risk factors for 
SUD. Furthermore, associations were nominally higher in females than in males (ORfemales = 1.59, 
95% CI: 1.19-2.12, ORmales = 1.18, 95% CI: 0.98-1.42).  
Conclusions A higher genetic liability to attention-deficit/hyperactivity disorder was associated 
with higher risks of substance use disorders in individuals with attention-deficit/hyperactivity 
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disorder. Results were robust across different types and severity levels of substance use disorders 
and when adjusting for other risk factors for substance use disorders.  
 
Keywords: attention-deficit/hyperactivity disorder, substance use disorder, polygenic risk, alcohol, 




Attention-deficit/hyperactivity disorder (ADHD) is a highly heritable neurodevelopmental disorder 
with childhood onset, (1) and more frequently diagnosed in males than in females.(2, 3) Among 
children with ADHD, up to 65% continue to have persistent symptoms and impairments in 
adulthood, although only about 15% continue to meet full criteria for the disorder.(4) 
In addition, children with ADHD are at increased risk of a range of adverse outcomes,(5, 6) 
including the development of substance use disorders (SUD).(7-9) In general, the risk of SUD 
increases through adolescence, to reach its maximum during early adulthood,(10, 11) with a faster 
progression rate in ADHD than in the general population.(12) In individuals with ADHD, known 
predictors of SUD include persistent ADHD,(13) being diagnosed with ADHD in later adolescence 
or adulthood,(14) and co-occurrence of oppositional defiant disorder and conduct disorder 
(ODD/CD).(8, 9, 15) Other factors, including male sex and parental SUD, have been identified as 
predictors of SUD in the general population in a large US study.(16) A Danish register-based study 
showed that ADHD increased the risk of SUD less in males than in females.(17)  
Recently, the first twelve genome-wide significant common risk alleles for ADHD were identified 
in the, to date, largest genome-wide association study (GWAS) meta-analysis of ADHD.(18) This 
meta-analysis included data from the Psychiatric Genomics Consortium (PGC) and the iPSYCH 
sample – a Danish case-cohort sample of genotyped cases with specific mental disorders, including 
ADHD, and a 2% genotyped random sample of the Danish population.(19) By including more risk 
alleles for ADHD, which did not attain genome-wide significance, composite measures of common 
genetic risk variants can be generated, expressed as polygenic risk scores for ADHD (PRS-
ADHD).(18) Using data from the UK Biobank, PRS-ADHD was found to be associated with higher 
self-reported alcohol intake frequency and dependency in adults without ADHD.(20) A recently 
published GWAS of cannabis use disorder found PRS-ADHD significantly associated with 
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cannabis use disorder,(21) and another study recently demonstrated a Single Nucleotide 
Polymorphism (SNP)-based genetic correlation between ADHD and lifetime cannabis use.(22) 
Other recently published studies found no strong evidence for an association between PRS-ADHD 
and SUD.(23, 24) In addition, PRS-ADHD have also been associated with persistence of 
ADHD(25) and comorbid ODD/CD.(26) Still, there is limited knowledge on whether genetic 
liability to ADHD is associated with the development of SUD in individuals with ADHD.  
To further elucidate the nature of the association between ADHD and SUD and to test whether 
genetic liability to ADHD is associated with SUD, the present study uses nationwide population-
based data available in the iPSYCH sample. The aims were to (1) estimate the association between 
PRS-ADHD and SUD, across different types and severity levels, in individuals with ADHD; (2) 
estimate the association between other risk factors and SUD, and (3) estimate the association 
between PRS-ADHD and SUD while accounting for other risk factors to assess the extent of 




We linked information from several Danish population-based registers using the unique personal 
identification number assigned to all individuals living in Denmark and registered in the Danish 
Civil Registration System since 1968.(27) This register also provides information on sex, date of 
birth, migration, death, and parents’ personal identification numbers.  
The Danish Newborn Screening Biobank, contains dried blood spots of practically all infants born 
in Denmark since May 1, 1981,(28) and for iPSYCH participants provided biological material for 
genotyping. Genetic information was linked with individual-level register-data. The Danish 
Psychiatric Central Research Register (DPCRR)(29) and the Danish National Patient Register 
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(DNPR)(30) providing information on clinical diagnoses according to the International 
Classification of Diseases, 8th and 10th editions (ICD-8 and ICD-10-Diagnostic Criteria for 
Research (DCR))(31, 32) and dates of hospital admissions and discharges. Inpatient contacts are 
registered since 1969 and 1977 in the DPCRR and DNPR, respectively, and outpatient contacts 
since 1995 in both registers. We obtained information on parental gross income and highest 
completed education from Statistics Denmark’s socioeconomic registers.(33) 
 
Study population 
The iPSYCH sample includes a total of 18 726 incident ADHD cases, identified in DPCRR (ICD-
10-DCR: F90.0), diagnosed before December 31, 2012.   
Biological material was available and passed the genetic quality control for 92% of those with 
ADHD (N = 17 249).(19) Information on the iPSYCH sample, the genotyping, and quality-control 
details have been published previously.(18, 19) We restricted our study population to individuals 
with an incident ADHD diagnosis after age 3, with both parents born in Denmark, born no later 
than December 31, 2003, alive and living in Denmark at age 13, and with no registered SUD 
diagnosis before age 13. We further restricted to unrelated individuals, and finally, to reduce 
population stratification and thereby improve accuracy of PRS-ADHD derived from samples of 
European ancestry,(34) a genetic homogenous sample was generated by restricting to individuals 
with European ancestry. This was done by excluding outliers based on a SNP-based principal 
component analysis (PCA). Methods for restricting to European ancestry and unrelated individuals 
are described in the supplementary material. Our final study population included 13 116 genotyped 
individuals with ADHD. Numbers of individuals excluded at each step are provided in Table S1. 
 
Substance use disorders (SUD) 
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We defined any SUD as at least one ICD-10 diagnosis of SUD (F10-F19) registered after the 13th 
birthday, in DNPR or DPCRR, regardless of the timing of the first registered ADHD diagnosis. In 
addition, we categorized SUD into three types: alcohol, cannabis, and other illicit drugs. Finally, we 
hierarchically ordered severity of SUD into three mutually exclusive levels, based on the first 
decimal in ICD-10 codes (as shown in Table 2): use (F1x.0), abuse (F1x.1), and addiction (F1x.2), 
with addiction representing the most severe clinical phenotype. We excluded SUD diagnoses for 
nicotine use (ICD-10: F17) due to low prevalence (1%), likely due to underreporting of smoking in 
the registries.  
 
Polygenic risk scores for ADHD (PRS-ADHD) 
PRS-ADHD were derived in the iPSYCH sample based on the European ADHD GWAS meta-
analysis summary statistics.(18) Scores were calculated as the sum of ADHD risk alleles carried by 
an individual in the target sample, where each genetic variant was weighted by the corresponding 
log-odds ratio from the association with ADHD in the discovery sample. Because the Danish 
iPSYCH ADHD sample constitutes the majority of the entire PGC ADHD sample, scores were 
calculated using a ‘leave-one-out approach’. Cases and controls were split into five groups, and 
each of these groups were consecutively used as the target sample, using the other four groups plus 
PGC samples as the discovery sample (details in the supplementary material and elsewhere (18)). 
Main results are presented for PRS-ADHD at a SNP p-value threshold of 0.2, maximally capturing 
variance in the original ADHD GWAS.(18)  
Finally, we standardized the PRS-ADHD within the five target samples and created deciles. 
 
Risk factors for SUD 
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We assessed sex (male vs. female) and age at first ADHD diagnosis (≥13  13 years vs. < 13 years) 
as well as other risk factors for SUD described in the following. Comorbid ODD/CD was defined as 
a diagnosis of either disorder (ICD-8: 308.03-06, ICD-10: F90.1, F91) in DPCRR or DNPR, from 
birth and throughout the study period. Parental history of SUD and of any mental disorder was 
identified if either parent had an SUD diagnosis or a diagnosis of any mental disorder  (for ICD 
codes, see Table S2). Parental socioeconomic status (SES) was defined using previously published 
definitions.(17) Low paternal income was identified as a gross income in the lowest quintile, based 
on income for all adult males in the iPSYCH sample in a given calendar year. Low maternal 
education was defined as having compulsory school education only, usually obtained by age 16. 
These parental psychiatric and socioeconomic factors were obtained as the last registered 
information before or during the year the child turned 13 years of age. 
 
Statistical analyses 
We estimated odds ratios (ORs) using logistic regression models to examine associations between 
PRS-ADHD and SUD. The PRS-ADHD were scaled to range from 0 (lowest decile) to 1 (highest 
decile) and was included as a continuous variable in the primary analyses. One unit increase in 
PRS-ADHD thus corresponds to a comparison between the highest and the lowest decile. To 
account for the varying time at risk for SUD, we calculated the observation time as the number of 
days from age 13 until death, emigration or December 31, 2016, whichever came first. Main 
analyses were adjusted for observation time, sex, age and calendar year at first ADHD diagnosis 
(both included as continuous measurements), and the first four principal components (PCs) to adjust 
for potential remaining population stratification. PCs were obtained from a SNP-based PCA 
conducted in the final study population (see supplementary material). First, we estimated ORs for 
the association between PRS-ADHD and SUD. Second, we evaluated other risk factors for SUD by 
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estimating ORs in independent models. To evaluate the amount of variation in SUD explained by 
each factor, we additionally estimated Nagelkerke’s R2 (35) and a transformation to the liability 
scale as proposed by Lee et al. (36) assuming a population prevalence of SUD of 40%.(22, 37) 
Third, we included each risk factor one by one in the main model, ranked by their estimated amount 
of variance explained, to investigate whether an association between PRS-ADHD and SUD could 
be explained by any of these factors. Analyses were repeated for each SUD type and severity level, 
defined as binary outcome variables.   
Moreover, we tested for interactions between PRS-ADHD and the other risk factors for SUD. For 
each analysis, interactions with other covariates were included in the model.(38) We repeated the 
main analyses in males and females, separately. Finally, to evaluate each risk factor as a potential 
confounder of mediator, we assessed their association with PRS-ADHD, by calculating mean PRS-
ADHD differences between levels of each risk factor for SUD, and evaluated these by t-tests.  
All estimates are accompanied by 95% confidence intervals (CIs), and estimates were declared 
statistically significant at the 5% level, if not otherwise stated. R2 and liability estimates were 
accompanied by non-parametric 95% CIs using bootstrap resampling with 10 000 replications, 
estimated in SAS version 9.4 (SAS Institute Inc., Cary, NC). The main analyses were conducted 
using Stata version 15.(39) The PCs used for outlier removal were calculated in EIGENSOFT 




To check robustness of results, we repeated the main analysis with PRS-ADHD based on different 
p-value thresholds for SNPs included. In addition, we used different values of assumed population 
prevalence of SUD in ADHD for the transformation of R2 into the liability scale. Finally, we 
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conducted sensitivity analyses to evaluate the impact of applying different cohort restrictions in 




Among the 13 116 individuals with ADHD, 9 680 were males (73.8%) and 3 436 were females 
(26.2%). Median age at first ADHD diagnosis was 11.5 years (inter-quartile range (IQR) 8.4-17.3), 
with higher ages in females (median 15.1 years, IQR 9.7-19.8) than in males (median 10.7 years, 
IQR 8.1-15.9). In total, 2 368 (18.1%) individuals with ADHD developed SUD: 1 731 of these were 
males (73.1%) and 637 were females (26.9%). Median age at first SUD diagnosis was 19.4 years 
(IQR 17.2–22.3 years). Characteristics of the study population are presented separately for ADHD 
individuals with and without SUD (Table 1).  
 
PRS-ADHD and SUD 
In the main analyses, adjusted for observation time, sex, age and calendar year at first ADHD 
diagnosis, and the first four PCs, we found an association between PRS-ADHD and risk of any 
SUD (OR = 1.30, 95% CI: 1.11-1.51). PRS-ADHD explained approximately 0.2% of the variation 
in SUD on the liability scale (Table 2). Figure 1 shows the ORs for any SUD by deciles of PRS-
ADHD, with the lowest decile as the reference. 
Across different types of SUD, associations were observed for alcohol, OR = 1.26 (95% CI: 1.04-
1.53) and cannabis, OR = 1.34 (95% CI: 1.10-1.64). Across different levels of severity, associations 
were observed for substance use, OR = 1.36 (95% CI: 1.02-1.80), and addiction, OR = 1.30 (95% 
CI: 1.07-1.57). Associations with other illicit drugs, OR = 1.21 (95% CI: 0.99-1.50) and SUD 
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abuse, OR = 1.21 (95% CI: 0.88-1.65) were less robust with confidence intervals crossing 1 (Figure 
2 and Table 3).  
 
Influence of other risk factors for SUD 
The ORs with 95% confidence intervals across all SUD outcomes for individual associations with 
the different risk factors for SUD are illustrated in Figure 2 and presented in Table S3.   
The factors most strongly associated with SUD, across types and severity levels, were higher age at 
first ADHD diagnosis, OR = 3.28 (95 % CI: 2.75-3.92) and comorbid ODD/CD, OR = 2.87 (95% 
CI: 2.53-3.26). Comorbid ODD/CD was the factor explaining the largest proportion of variation in 
SUD, as estimated by Nagelkerke’s R2 (3.6%) and on the liability scale (5.6%) (Table 2). All SUD 
risk factors, except sex and age at ADHD diagnosis, were associated with PRS-ADHD, as estimated 
by differences in mean PRS-ADHD and p-values evaluated according to a Bonferroni-corrected p-
value threshold of 0.007, (Table S4). No evidence of interaction with PRS-ADHD were found for 
any of the risk factors (Table S5). Associations between PRS-ADHD and any SUD were somewhat 
attenuated, but remained, after adjusting for the other SUD risk factors (Table 3). Similar results 




In analyses stratified by sex, we found the strongest association between PRS-ADHD and SUD in 
females (OR = 1.59, 95% CI: 1.19-2.12), and less robust association in males (OR = 1.18, 95% CI: 
0.98-1.42). For specific types and severity levels of SUD, the conclusions were overall the same. 
However, in males, we found some evidence for an association with cannabis use, OR = 1.26 (95% 
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CI: 1.01-1.60). In females, we observed no association with alcohol, OR = 1.22 (95% CI: 0.86-
1.73), but an association with other illicit drugs, OR = 1.78 (95% CI: 1.18-2.69) (Table S6). 
 
Sensitivity analyses 
When we repeated the main analysis with PRS-ADHD based on different p-value thresholds, the 
effect sizes were largely unchanged across different thresholds (Table S7). Estimated proportion of 
variance of SUD on the liability scale was largely the same regardless of SUD population 
prevalence assumed (k=35%, 40%, 45%) (Table S8). The variance explained was slightly increased 
when including the original continuous and standardised PRS-ADHD instead of the categorized 
PRS-ADHD in the main analysis (0.26% vs. 0.23%). 
Moreover, results were robust to PRS-ADHD based on the iPSYCH sample in the discovery sample 
only, across different adjustments for genetic population structure, and across different cohort 
selections (Table S9).   
 
Discussion 
This is the first study to examine whether PRS-ADHD is associated with SUD in ADHD, with 
several novel findings. First, we found that a higher PRS-ADHD increased the risk of any SUD, as 
well as different SUD types and severities. However, we did not find evidence for association with 
other illicit drugs, and we found no hierarchy of associations with increasing level of SUD severity. 
Second, we present novel findings on other risk factors for SUD in ADHD, including late diagnosis 
of ADHD (after age 13 years), known SUD or mental disorders in parents, and low parental SES, 
which were all individually associated with increased risks of SUD in individuals with ADHD. In 
comparison, the PRS explained a much smaller proportion of the variance in SUD. Third, we found 
that the association of PRS-ADHD with SUD existed over and above what could be explained by 
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the other risk factors, and was mainly driven by cannabis use. Finally, we observed stronger 
associations in females. For both males and females, we found an association between PRS-ADHD 
and cannabis use disorder. 
 
ADHD is a highly heritable disorder and yet only a few studies have examined whether genetic 
liability to ADHD is associated with an increased risk of SUD, and to our knowledge, no previous 
study has investigated this association among individuals with ADHD. Our results corroborate the 
recent finding of a genetic correlation between ADHD and lifetime cannabis use disorder, based on 
summary statistics from GWAS meta-analyses.(21, 22) However, a case-control study in a Spanish 
population found no association between PRS-ADHD and SUD as estimated by R2, probably due to 
lack of power.(24) Additionally, a study of 1 050 African Americans found no evidence of an 
association between PRS-ADHD and marijuana use disorders.(44)  
 
Our finding of stronger associations between PRS-ADHD and SUD in females than in males is 
intriguing and requires further research. Some previous observational studies of ADHD samples 
suggest higher relative risks of SUD and other adverse outcomes in females than in males,(5, 17) 
probably explained by females with ADHD often being perceived as less impaired than males,(45) 
and the higher referral threshold for females.(46) Hence, ADHD severity (and not only the presence 
of an ADHD diagnosis) may increase the risk of SUD more in females than in males, as indicated 
by the present study. Despite strong evidence for associations between ADHD and SUD, little is 
known regarding risk factors for this. We identified, in addition to PRS-ADHD, several other risk 
factors for SUD in ADHD (e.g. late diagnosis of ADHD and parental history of SUD, mental 
disorders, and low SES), some of which are known to be associated with SUD in the general 
population.(47, 48) Comorbid ODD/CD was associated with higher PRS-ADHD and was the 
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strongest risk factor for SUD, in terms of the amount of variance explained. Still, no sufficient 
evidence of an interaction with PRS-ADHD was found, and the association we found between PRS-
ADHD and SUD, was not fully explained by the presence of comorbid ODD/CD.  
 
This was a nationwide population-based study on the largest genotyped ADHD-sample, based on 
information on clinical diagnoses of mental disorders made by psychiatrists. However, our study 
also had several limitations. First, only diagnoses from hospital contacts are included in the Danish 
registers and SUD is underreported by clinicians.(49) Hence, the prevalence of SUD is likely 
underestimated and our study may only include a smaller proportion of those with the lowest 
severities of SUD (use and abuse). In addition, the possibility of misclassification of ADHD and 
SUD cannot be excluded. Still, the validity of clinical ADHD and SUD diagnoses in the registers 
has been shown to be high.(50, 51) Furthermore, the prevalence of ADHD diagnoses and treatment 
in Denmark is low.(52) In order to include as many ADHD cases as possible, and based on the 
hypothesis of a shared genetic liability increasing the risk of both disorders, we did not take the 
order of diagnoses into account. This may have influenced our estimation of the effect of age at 
ADHD diagnosis on risk of SUD. However, in our sensitivity analyses of individuals diagnosed 
with ADHD before age 13, the association between older age at ADHD diagnosis and SUD 
remained, as did the association between PRS-ADHD and SUD. Similarly, PRS-ADHD predicted 
SUD in cases with no SUD before first ADHD diagnosis. Second, collider bias is a fundamental 
concern in progression studies.(53) More specifically, by conditioning on ADHD, a spurious 
correlation between the PRS-ADHD and SUD can be introduced through factors such as sex, that 
both affect ADHD onset as well as SUD. In this particular case, this spurious correlation is removed 
by adjusting for sex. In the present study, we only assessed genetic liability to ADHD on the risk of 
SUD. Future research should include measures of other genetic liabilities, such as genetic liability 
16 
 
to SUD and other mental disorders, to evaluate whether these are more or less predictive of SUD. 
Other limitations were that the present study design did not enable us to account for use of 
medication and that we were unable to study nicotine use disorder due to very few diagnoses in the 
registers, as smoking is underreported. In addition, other imprecisions in our register-data may 
explain part of the association between genetic liability to ADHD and SUD, e.g. depression 
diagnosed during childhood or imperfect classification of SES by parental education and income 
levels. Finally, the variance in SUD explained by PRS-ADHD was small, also compared to other 
individual and family-related risk factors. This is in line with previous research demonstrating that 
the trait variance in ADHD status explained by the PRS is modest, and the variance explained for 
secondary outcomes is even lower.(20) PRS prediction may be improved by including larger 
sample sizes and other genetic factors such as copy number and rare as well as intermediate 
frequency variants.(18, 54) 
 
In conclusion, this is, to our knowledge, the first study to find evidence that genetic liability to 
ADHD, indexed by PRS, is associated with higher risk of SUD in individuals with ADHD. Male 
sex, higher age at ADHD diagnosis, comorbid ODD/CD, parental factors (SUD, mental disorders, 
low paternal income, and low maternal education) were also identified to be associated with SUD in 
ADHD. The association between a genetic liability to ADHD with respect to common variants and 
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Figure 1: Association between polygenic risk score for ADHD (PRS-ADHD) and any substance use disorders (SUD). Odds ratios and 
95% confidence intervals for SUD are presented by deciles of the PRS-ADHD, in comparison to the lowest decile (reference). Analyses 
were adjusted for observation time, sex, age and calendar year at first ADHD diagnosis, and population stratification.  
 
 
Figure 2: Forest plot of polygenic risk score for ADHD (PRS-ADHD) and other risk factors and their associations with any substance use 
disorder (SUD), SUD type, and SUD severity. The factors include: PRS-ADHD; coded in deciles but included continouosly and ranging 
from 0 to 1), sex (male vs. female), age at first ADHD-diagnosis (≥13 years vs. < 13 years), presence of comorbid oppositional defiant 
disorder/conduct disorder (ODD/CD), parental SUD, parental mental disorders, paternal income in the lowest quintile, and low maternal 
education (having compulsory education as the highest completed level of education). Associations were estimated as odds ratios for SUD, 
with 95% confidence intervals. Analyses were adjusted for observation time, sex, age and calendar year at first ADHD diagnosis (and in 















Patient-related factors    
PRS-ADHD €, mean (SD) 0.06 (0.99) -0.01 (1.00) 0.00 (1.00) 
Male sex, N (%) 1 731 (73.1)  7 949 (74.0) 9 680 (73.8) 
ODD/CD, N (%) 558 (23.6) 1 263 (11.8) 1 821 (13.9) 
Age at first ADHD ≥13 years &, N (%) 1 865 (78.8) 3 695 (34.4) 5 560 (42.4) 
Age at first ADHD, median (IQR) 18.6 (14.1-22.7) 10.5 (8.0-15.2) 11.5 (8.4-17.3) 
Calendar year at first ADHD, median (IQR) 2009 (2006-2011) 2008 (2005-2010) 2008 (2005-2010) 
Age at first ODD/CD, median (IQR) 16.2 (13-20) $ 10.3 (7.6-14.6) 12.2 (8.2-16.4) 
Age at first SUD, median (IQR) 19.4 (17.2-22.3) - - 
Observation time (years), median (IQR) 13.6 (10.6-17.1) 7.7 (4.0-11.9) 9.0 (4.6-13.4) 
Family-related factors 
   
Parental SUD, N (%) 460 (19.4) 1 468 (13.7) 1 928 (14.7) 
Parental mental disorder, N (%) 868 (36.7) 3 719 (34.6) 4 587 (35.0) 
Paternal income (low), N (%) 479 (20.2) 1 530 (14.2) 2 009 (15.3) 
Maternal education (low), N (%) 1 071 (45.2) 3 325 (30.9) 4 396 (33.5) 
Abbreviations: ADHD: attention-deficit/hyperactivity disorder. PRS: polygenic risk score. SUD: substance use disorder. ODD/CD: oppositional defiant disorder/conduct disorder.  
€ The polygenic risk score is here included as a continuous normally distributed variable standardized within target-groups (defined by the ‘leave-one-out’-approach for calculating the 
PRS-ADHD) in the final study population (n=13 116). 
$ Numbers were based on few individuals and rounded due to data regulations at Statistics Denmark. 































Table 2: Associations between a range of risk factors and any SUD in individuals with ADHD (N=13 116), expressed as ORs, with 95% CIs. The proportion 
of variance in SUD explained by each risk factor is estimated by Nagelkerke’s R2 and a transformation to the liability scale.  
Risk factors OR (95% CI) € R2Nagelkerke (95% CI) $ 
(%) 
R2liability (95% CI) $ 
(%) 
PRS-ADHD § 1.30 (1.11-1.51) 0.14 (0.02-0.38) 0.23 (0.03-0.60) 
Male sex 1.46 (1.30-1.63) 0.61 (0.29-1.11)  0.96 (0.46-1.64)  
Age at first ADHD ≥13 years & 3.28 (2.75-3.92) 2.26 (1.63-2.98)  3.57 (2.58-4.70)  
ODD/CD 2.87 (2.53-3.26) 3.58 (2.71-4.51)  5.63 (4.29-7.08)  
Parental SUD 1.83 (1.60-2.08) 1.06 (0.63-1.61)  1.69 (1.01-0.03)  
Parental mental disorder 1.59 (1.43-1.76) 0.99 (0.58-1.51)  1.58 (0.92-2.40)  
Paternal income (low) 1.46 (1.29-1.66) 0.47 (0.20-0.85)  0.75 (0.31-1.35)  
Maternal education (low) 1.25 (1.13-1.38) 0.26 (0.07-0.56)  0.41 (0.12-0.89)  
Abbreviations: SUD: substance use disorder. ADHD: attention-deficit/hyperactivity disorder. OR: odds ratio. CI: confidence interval. PRS: polygenic risk score. ODD/CD: 
oppositional defiant disorder/conduct disorder. 
€ Analyses were adjusted for observation time, sex and age and calendar year at first ADHD diagnosis. For the PRS-ADHD, the model additionally included the first four 
principal components to adjust for remaining population stratification. 
$ All estimates were based on log likelihood estimates from logistic regression analyses comparing models with and without the factor of interest. All models were adjusted 
for observation time, calendar year at first ADHD diagnosis, the first four principal components. Analyses were not adjusted for sex and age at first ADHD diagnosis for a 
meaningful model comparability. Nagelkerke’s R2 was estimated and transformed to the liability scale as proposed by Lee et al. (36) assuming a population prevalence of 
SUD of 40%.(22, 37) R2 measures were accompanied by non-parametric 95% CIs using bootstrap resampling with 10 000 replications. 
§ The ADHD-PRS was categorized into deciles but included continuously yielding ORs corresponding to comparison of the highest decile to the lowest.  






Table 3: Associations between the PRS-ADHD and different types of SUD and of different severity levels of SUD in individuals with ADHD (N=13 116), expressed 
as ORs, with 95% CIs, in different adjustment models. 
  Types of SUD§ Severity levels of SUD& 
The different covariates 








Other illicit drugs 







OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
M1: PRS-ADHD€, minimal 
adjustment$ 
1.30 (1.11-1.51) 1.26 (1.04-1.53) 1.34 (1.10-1.64) 1.21 (0.99-1.50) 1.36 (1.02-1.80) 1.21 (0.88-1.65) 1.30 (1.07-1.57) 
M2: M1 + ODD/CD 1.25 (1.07-1.47) 1.23 (1.01-1.50) 1.30 (1.06-1.60) 1.17 (0.95-1.45) 1.34 (1.01-1.77) 1.19 (0.87-1.63) 1.27 (1.05-1.54) 
M3: M2 + Parental SUD 1.23 (1.06-1.44) 1.21 (0.99-1.47) 1.29 (1.05-1.58) 1.15 (0.93-1.42) 1.32 (0.99-1.75) 1.18 (0.86-1.62) 1.25 (1.02-1.51) 
M4: M3 + Parental psych 1.23 (1.05-1.44) 1.20 (0.99-1.47) 1.28 (1.05-1.57) 1.14 (0.92-1.41) 1.31 (0.99-1.73) 1.17 (0.85-1.61) 1.24 (1.02-1.51) 
M5: M4 + Paternal income 1.22 (1.04-1.42) 1.20 (0.99-1.47) 1.27 (1.04-1.56) 1.12 (0.91-1.39) 1.32 (0.99-1.75) 1.14 (0.83-1.57) 1.22 (1.00-1.48) 
M6: M5 + Maternal education 1.21 (1.03-1.41) 1.20 (0.98-1.46) 1.28 (1.04-1.57) 1.11 (0.90-1.38) 1.31 (0.99-1.74) 1.13 (0.82-1.56) 1.21 (1.00-1.48) 
Abbreviations: SUD: substance use disorder. ADHD: attention-deficit/hyperactivity disorder. PRS: polygenic risk score. SUD: substance use disorder. OR: odds ratio. CI: confidence 
interval. ODD/CD: oppositional defiant disorder/conduct disorder. 
€ The PRS-ADHD was categorized into deciles but included continuously yielding ORs corresponding to comparison of the highest decile to the lowest. 
$ Adjusted for observation time, sex and age and calendar year at first ADHD diagnosis, and the first four principal components to adjust for remaining population stratification. 
§ Not mutually exclusive groups. Individuals with ADHD and several types of SUD are included in more than one group. 
& Hierarchically ordered into mutually exclusive groups, with the following total sample sizes: Use (N=11 270), abuse (N=11 162), and addiction (N=12 180). In all three analyses, the 
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Calculation of polygenic risk scores for ADHD (PRS-ADHD) 
PRS-ADHD were derived from summary statistics in the meta-analysis in recently published genome-wide-association study (GWAS),(1) 
applied in the iPSYCH2012 case-cohort sample.(2) Polygenic risk scores were based on summary statistics from the GWAS meta-analysis 
including both the iPSYCH2012 case-cohort sample (14 584 cases and 22 492 controls) as well as the 10 samples with European ancestry 
from the Psychiatric Genomics Consortium (PGC) (4 578 cases and 11 912 controls). The specific samples and genotyping procedure are 
described in detail elsewhere.(1) To include information from the iPSYCH2012 case-cohort sample in the discovery sample, PRS were 
calculated in a so-called ‘leave-one-out’ approach: Individuals in the iPSYCH2012 case-cohort sample were split into five target groups. 
This was done so that the discovery and target datasets were non-overlapping by assigning the 23 waves into five groups, distributing the 
total number of individuals, the number of ADHD cases, and birth years as equal as possible across the five target groups. Polygenic risk 
scores were then estimated using the ricopili pipeline(3) for each of the five target samples. Risk alleles were identified in a GWAS on 
potential risk alleles for ADHD in a discovery sample consisting of the 10 PGC European samples and iPSYCH sample leaving out the 
target group. Scores were calculated as the sum of the ADHD risk alleles identified from the GWAS meta-analysis as SNPs passing a 
specific significance threshold and weighted by the effect sizes identified in the discovery sample. To assign a PRS to all individuals in the 
iPSYCH sample, this procedure was repeated for each of the five target groups. PRS were calculated for each of the following 10 
significance thresholds: 0.00000005, 0.000001, 0.0001, 0.001, 0.01, 0.05, 0.1, 0.2, 0.5, 1. Within target datasets, only SNPs intersecting 
across all genotyping waves with an info score of at least 0.6 and a MAF of at least 0.01 were used when calculating PRS. Following 
Demontis et al.,(1) for the main analyses we included SNPs at a p-value threshold at 0.2, optimizing the variance explained according to 
ADHD case status. For this chosen threshold the number of SNPs included in the PRS calculation ranged from 61 179 (target group 1) to 
 3 
61 637 (target group 4). Additionally, 10 PRSs, one for each p-value threshold, were similarly calculated excluding the PGC European 
samples in the discovery sample. Finally, we standardized the PRS-ADHD within the five target samples and generated deciles.  
 
Method for restriction to European ancestry and unrelated individuals 
The training of the PRS-ADHD was based entirely on European samples and thus may be biased in populations of non-European 
ancestry.(4) We initially restricted our target dataset to ADHD cases with both parents born in Denmark to include parental information 
from the registers. Still, there might be remaining ancestry outliers, and we therefore further restricted our study population to individuals 
with European ancestry. This was done following a standard principal component analysis (PCA)-based approach similar to what has been 
done in the ADHD GWAS meta-analysis.(1)In order to identify population substructure and ancestry, we used principal components (PCs) 
from a PCA conducted for 81 620 individuals using EIGENSOFT version 6.1.4(5) on a relatedness-pruned set of individuals and a subset 
of SNPs. Further description for this PCA procedure as well as a visual inspection of the first principal components (PCs) showing clear 
patterns of population structure can be found in Pedersen et al. 2018(6).  
We calculated a mean and standard deviation of each of the first three principal components in a population of individuals in the entire 
iPSYCH sample with all four grandparents born in Denmark. From the estimated parameters, we removed all with values outside a three-
dimensional ellipsoid centered at the estimated means and with an ellipsoid at a distance of six standard deviations from the mean in each 
direction.   
Next, we removed genetically close related individuals by identifying individuals with an estimated relatedness coefficient of � > 0.2 in 
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plink version 1.9,(7-9) and kept one of the related individuals, including as many unrelated individuals as possible in our final study 
population. 
Last, we calculated new PCs based on our study population after restriction to European ancestry and without close relationships to check 
for remaining population structure. The PCA was based on an LD-pruned set of SNPs (from 496,370 to 25,085, conducted in plink version 
1.9 with the following parameters window-size = 1500 kb, step-size = 500, r2 = 0.02). After further excluding 9 SNPs with a high loading 
on the first PC, causing approximately 50 outliers from genotyping wave number 23 and therefore likely to be genotyping errors, a PCA 
resulted in PCs indicating no remaining population stratification. Furthermore, we tested correlations between the calculated PCs and the 
PRS-ADHD as well as our outcome of SUD, and found only week evidence of an association with the first 10 PCs. We decided to include 
the first four PCs in the main analyses, and to evaluate the sensitivity of results, we repeated the main analysis including no PCs and 10 
PCs, respectively, in the analysis.  
 
Additional sensitivity analyses 
We conducted several additional sensitivity analyses, using different model specifications and study populations, to check robustness of our 
main estimate for the association between PRS-ADHD and SUD. These analyses are described in the following and the results are 
presented in Table S8. 
First, we calculated PRS-ADHD excluding the PGC samples in the discovery sample, i.e. using summary statistics entirely based on the 
iPSYCH sample. Next, we investigated the impact of the number of principal components included in the model by repeating the analysis 
including no and the first 10 PCs, respectively. In the main analysis, we initially restricted our cohort to individuals born in Denmark with 
 5 
Danish-born parents (initial ADHD cohort), and then further restricted to genetically unrelated individuals and individuals with European 
ancestry. This was done in accordance with pertinent research(10, 11) to ensure that the PRS-ADHD were applied in a homogeneous 
Danish population with non-European ancestry. However, to explore robustness and generalizability of results to the less restrictive initial 
ADHD cohort, we explored the association, without excluding genetically related individuals and individuals with a 3rd generation non-
European ancestry. Third, to evaluate the impact of the timing of exposure and outcome, analyses were also repeated for ADHD sub-
cohorts ensuring that the ADHD diagnosis was not given after the first SUD diagnosis. This was done by restricting the cohort to 
individuals with no SUD diagnosis before first ADHD diagnosis and by restricting the cohort to individuals with the first ADHD diagnosis 
before age 13. Finally, we restricted to ADHD cases with 10 years observation time after age 13 years. This restriction included the older 
birth cohorts, but ensured same time at risk of being diagnosed with SUD. 
As demonstrated in Table S8, these changes to the model and cohort restrictions barely changed the estimates, as compared to our main 
analysis.  
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Table S1: Study population, applying different cohort restrictions    
Inclusion criterion Excluded, n (%)  Included, n 
All sampled as ADHD-cases in iPSYCH2012€  18 726 
Individuals with biological material available in the Danish Neonatal Screening Biobank 891 (4.8) 17 835 
Passing genetic quality control 586 (3.3) 17 249 
Non-missing information on PRS-ADHD 195 (1.1) 17 054 
Parents born in Denmark 2202 (12.9) 14 852 
Ignoring ADHD diagnoses before age 3 84 (0.6) 14 768 
Born before Dec 31, 2003 (to enable follow-up from age 13) 662 (4.5) 14 106 
Alive, not emigrated from Denmark before age 13 7 (0.0) 14 099 
No SUD before age 13 31 (0.0) 14 068 
Restricting to unrelated individuals 756 (5.4) 13 312 
Restricting to European ancestry 196 (1.5) 13 116 
Abbreviations: ADHD: attention-deficit/hyperactivity disorder. PRS: polygenic risk score. SUD: substance use disorder. 
€ Inclusion criteria used in the iPSYCH-sample: Individuals born in Denmark between May 1, 1981 – Dec 31, 2005, known mother, ADHD defined as ICD-10 diagnosis F90.0 after age 1 




Table S2: ICD-8 and ICD-10 diagnostic codes used for different disease categories$ 
Disease ICD-8 ICD-10 
   
ADHD 308.01§ F90.0, F98.8§ 
Any Substance use disorder (SUD)  F10-F19 
Types of SUD   
     Alcohol  F10 
                       Cannabis  F12 
                       Other illicit drugs  F11, 13-16, 18-19 
Severity levels of SUD   
                       Use  F1x.0 
                       Abuse  F1x.1, F1x.8, F1x.9 
                       Addiction  F1x.2, F1x.3, F1x.4, F1x.5, F1x.6, F1x.7 
ODD/CD 308.03-06 F90.1, F91 
Parental mental disorders 290-315 F00-F99 
Parental SUD 291.x9, 294.39, 303.x9, 303.20, 303.28, 303.90, 304.x9 F10-F19 
Abbreviations: ICD-8 and ICD-10: The International Classification of Diseases, 8th and 10th edition. ADHD: attention-deficit/hyperactivity disorder. SUD: substance use disorder. 
ODD/CD: oppositional defiant disorder/conduct disorder. 
$ Identical with the definitions previously published by Pedersen CB, Mors O, Bertelsen A, Waltoft BL, Agerbo E, McGrath JJ et al. A comprehensive nationwide study of the incidence 
rate and lifetime risk for treated mental disorders. JAMA Psychiatry 2014; 71(5): 573-581. 










Table S3: Associations between a range of risk factors and different types of SUD and of different severity levels of SUD in individuals with ADHD (N=13 
116), expressed as ORs with 95% CIs. € Numbers equal the estimates presented in Figure 2. 
 
 
Types of SUD§ Severity levels of SUD& 















Risk factors OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
PRS-ADHD$ 1.30 (1.11-1.51) 1.26 (1.04-1.53) 1.34 (1.10-1.64) 1.21 (0.98-1.50) 1.36 (1.02-1.80) 1.21 (0.88-1.65) 1.30 (1.07-1.57) 
Male vs. female sex 1.46 (1.30-1.63) 1.08 (0.94-1.24) 1.84 (1.57-2.16) 1.67 (1.43-1.96) 0.90 (0.74-1.09) 1.17 (0.93-1.46) 2.02 (1.74-2.34) 
Age at first ADHD ≥13 years 3.28 (2.75-3.92) 3.17 (2.53-3.97) 3.33 (2.64-4.19) 3.95 (3.07-5.09) 3.12 (2.29-4.25) 3.68 (2.58-5.23) 3.24 (2.59-4.04) 
ODD/CD 2.87 (2.53-3.26) 2.16 (1.84-2.52) 2.65 (2.26-3.10) 3.63 (3.08-4.27) 1.94 (1.53-2.47) 2.79 (2.18-3.57) 3.29 (2.81-3.84) 
Parental SUD 1.83 (1.60-2.08) 1.73 (1.47-2.02) 1.62 (1.38-1.92) 1.96 (1.66-2.32) 1.72 (1.37-2.17) 2.16 (1.69-2.76) 1.76 (1.49-2.06) 
Parental mental disorder 1.59 (1.43-1.76) 1.51 (1.33-1.72) 1.41 (1.23-1.62) 1.74 (1.52-2.01) 1.62 (1.35-1.96) 1.72 (1.40-2.13) 1.53 (1.34-1.74) 
Paternal income (low) 1.46 (1.29-1.66) 1.24 (1.06-1.45) 1.34 (1.14-1.58) 1.61 (1.37-1.90) 1.08 (0.85-1.39) 1.72 (1.35-2.19) 1.54 (1.32-1.79) 
Maternal education (low) 1.25 (1.13-1.38) 1.19 (1.05-1.35) 1.06 (0.93-1.21) 1.32 (1.15-1.51) 1.21 (1.00-1.46) 1.35 (1.10-1.66) 1.25 (1.10-1.41) 
Abbreviations: SUD: substance use disorder. ADHD: attention-deficit/hyperactivity disorder. OR: odds ratio. CI: confidence interval. PRS: polygenic risk score. ODD/CD: oppositional 
defiant disorder/conduct disorder. 
€ All analyses were adjusted for observation time, sex and age and calendar year at first ADHD diagnosis, and the first four principal components to adjust for remaining population 
stratification. 
$ The PRS-ADHD was included continuously in the models, and estimates correspond to a comparison of the highest vs. lowest decile of PRS-ADHD.  
§ Not mutually exclusive groups. Individuals with ADHD and several types of SUD are included in more than one group. 
& Hierarchically ordered into mutually exclusive groups, with the following total sample sizes:  Use (N=11 270), abuse (N=11 162), and addiction (N=12 180). In all three analyses, the 




Table S4: Mean PRS-ADHD differences in risk factors for SUD 
Risk factors Mean difference in PRS-ADHD €  (95% CI) p $ 
Male vs. female sex -0.01 (-0.05-0.03) 0.49 
Age at first ADHD ≥13 years -0.03 (-0.06-0.01) 0.15 
ODD/CD 0.14 (0.09-0.18) <0.0001 
Parental SUD 0.08 (0.04-0.13) <0.001 
Parental mental disorder 0.07 (0.04-0.11) <0.0001 
Paternal income (low) 0.17 (0.12-0.22) <0.0001 
Maternal education (low) 0.14 (0.10-0.18) <0.0001 
Abbreviations: ADHD: attention-deficit/hyperactivity disorder. PRS: polygenic risk score. SUD: substance use disorder. CI: confidence 
interval. ODD/CD: oppositional defiant disorder/conduct disorder. 
€ The PRS-ADHD was here included as a continuous normally distributed variable standardized within target-groups (defined by the 
‘leave-one-out’ approach for calculating the PRS-ADHD) in the final study population (n=13 116). 





Table S5: Interactions between the PRS-ADHD and other risk factors for SUD 
Risk factors p-value $ for the interaction with PRS-ADHD € 
Male vs. female sex 0.07 
Age at first ADHD ≥13 years 0.39 
ODD/CD 0.07 
Parental SUD 0.31 
Parental mental disorder 0.06 
Paternal income (low) 0.56 
Maternal education (low) 0.33 
Abbreviations: ADHD: attention-deficit/hyperactivity disorder. PRS: polygenic risk score. SUD: substance use disorder. CI: confidence 
interval. ODD/CD: oppositional defiant disorder/conduct disorder. 
€ The PRS-ADHD was here included as a continuous normally distributed variable in the final study population (n=13 116). 
The models are adjusted for observation time, and further include the following covariates: sex and age and calendar year at first ADHD 
diagnosis, and the first four principal components to adjust for remaining population stratification. All interactions between covariates and 
the two interaction variables of interest were included in the models.  



















Table S6: Sex-specific associations between the PRS-ADHD and SUD.$ expressed as ORs with 95% CI,. € for types and severities of SUD, in males 
(n=9 680) and females (n=3 436). 
 
 
Types of SUD§ Severity levels of SUD& 




Abuse  Addiction  
 
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
All 1.30 (1.11-1.51) 1.26 (1.04-1.53) 1.34 (1.10-1.64) 1.21 (0.98-1.50) 1.36 (1.02-1.80) 1.21 (0.88-1.65) 1.30 (1.07-1.57) 
Males 1.18 (0.98-1.42) 1.26 (0.99-1.59) 1.26 (1.01-1.60) 1.06 (0.83-1.35) 1.15 (0.82-1.63) 1.28 (0.87-1.87) 1.16 (0.93-1.45) 
Females 1.59 (1.19-2.12) 1.22 (0.86-1.73) 1.58 (1.03-2.40) 1.78 (1.18-2.69) 1.77 (1.09-2.85) 1.05 (0.60-1.84) 1.76 (1.20-2.58) 
Abbreviations: ADHD: attention-deficit/hyperactivity disorder. PRS: polygenic risk score.  SUD: substance use disorder. OR: odds ratio. CI: confidence interval.  
€ All analyses were adjusted for observation time, and age and calendar year at first ADHD diagnosis, and the first four principal components to adjust for remaining population 
stratification. 
$ The polygenic risk score for ADHD (PRS-ADHD) was included continuously in the models, and estimates correspond to a comparison of the highest vs. lowest decile of PRS-
ADHD.  
§ Not mutually exclusive groups. Individuals with ADHD and several types of SUD are included in more than one group. 






Table S7: Associations between PRS-ADHD and SUD for 10 p-value thresholds for SNPs included to calculate the PRS-ADHD. ORs$ and 95% CIs are 
presented for individuals in the study population (n= 13 116). The PRS-ADHD used in the main analyses was based on the significance threshold of 0.2 
and is highlighted in grey. 
PRS score Significance threshold (max. p-value) Number of SNPs € OR (95%CI) 
1 0.00000005 7 1.02 (0.87-1.19) 
2 0.000001 26 1.05 (0.90-1.22) 
3 0.0001 319 1.07 (0.92-1.25) 
4 0.001 1477 1.16 (0.99-1.35) 
5 0.01 7676 1.25 (1.07-1.46) 
6 0.05 24 004 1.38 (1.19-1.61) 
7 0.1 38 726 1.36 (1.17-1.59) 
8 0.2 61 401 1.30 (1.11-1.51) 
9 0.5 106 739 1.34 (1.15-1.56) 
10 1 141 684 1.33 (1.14-1.55) 
Abbreviations: ADHD: attention-deficit/hyperactivity disorder. PRS: polygenic risk score. SUD: substance use disorder. SNP: single nucleotide polymorphism. OR: odds ratio. CI: 
confidence interval.  
€ The number presented is an average of the number of SNPs identified in the training data sets corresponding to the five target groups. For PRS-ADHD score number 8, the number 
of SNPs varies from 61 179 (group 1) to 61 637 (group 3). 







Table S8: Proportion of variance explained by a range of risk factors SUD in individuals with ADHD (N=13 116), estimated by 
Nagelkerke’s R2 and a transformation to the liability scale for different assumed population prevalences of SUD.  
Risk factors R2Nagelkerke (95% CI) € 
(%) 
R2liability (95% CI) € 
(%) 
Population prevalence of SUD (k)  k=35% k=40% k=45% 
PRS-ADHD $ 0.14 (0.02-0.38) 0.22 (0.03-0.58) 0.23 (0.03-0.60) 0.23 (0.03-0.60) 
Male sex 0.61 (0.29-1.11) 0.94 (0.45-1.64) 0.96 (0.46-1.64) 0.98 (0.47-1.69) 
Age at first ADHD ≥13 years 2.26 (1.63-2.98) 3.49 (2.52-4.61) 3.57 (2.58-4.70) 3.61 (2.61-4.81) 
ODD/CD 3.58 (2.71-4.51) 5.51 (4.23-6.95) 5.63 (4.29-7.08) 5.70 (4.39-7.21) 
Parental SUD 1.06 (0.63-1.61) 1.65 (0.98-2.49) 1.69 (1.01-0.03) 1.71 (1.00-2.57) 
Parental mental disorder 0.99 (0.58-1.51) 1.54 (0.90-2.35) 1.58 (0.92-2.40) 1.60 (0.93-2.42) 
Paternal income (low) 0.47 (0.20-0.85) 0.74 (0.31-1.34) 0.75 (0.31-1.35) 0.76 (0.32-1.38) 
Maternal education (low) 0.26 (0.07-0.56) 0.40 (0.11-0.89) 0.41 (0.12-0.89) 0.42 (0.12-0.90) 
Abbreviations: SUD: substance use disorder. ADHD: attention-deficit/hyperactivity disorder. OR: odds ratio. CI: confidence interval. PRS: polygenic risk score. 
ODD/CD: oppositional defiant disorder/conduct disorder. 
€  All estimates were based on log likelihood estimates from logistic regression analyses comparing models with and without the factor of interest. All models 
were adjusted for observation time, calendar year at first ADHD diagnosis, the first four principal components. Analyses were not adjusted for sex and age at first 
ADHD diagnosis for a meaningful model comparability. Nagelkerke’s R2 was estimated and transformed to the liability scale as proposed by Lee et al. (12) 
assuming a population prevalence of SUD of 35%, 40%, and 45%, respectively.(13, 14) R2 measures were accompanied by non-parametric 95% CIs using 
bootstrap resampling with 10 000 replications. 





Table S9: Additional sensitivity analyses. All estimates are based on a logistic regression with the PRS-ADHD as the exposure and any SUD as the outcome 
and adjustment similar to the main analysis (n=13 116), if not otherwise specified. 
Setting Total, n SUD, n (%) OR (95% CI) 
Main analysis€ 13 116 2 368 (18.1%) 1.30 (1.11-1.51) 
PRS-ADHD excluding PGC in the discovery sample 13 116 2 368 (18.1%) 1.30 (1.12-1.52) 
Including no principal components 13 116 2 368 (18.1%) 1.30 (1.11-1.51) 
Including the first 10 principal components 13 116 2 368 (18.1%) 1.30 (1.11-1.51) 
No restriction to genetically unrelated individuals or European ancestry$  14 068 2 530 (18.0%) 1.33 (1.14-1.54) 
No PCA-based restriction to European ancestry$  13 312 2 400 (18.0%) 1.30 (1.11-1.51) 
Restricting to ADHD cases with no SUD diagnosis before first ADHD diagnosis  12 309 1 561 (12.7%) 1.28 (1.08-1.53) 
Restricting to ADHD cases diagnosed with ADHD before age 13 7 556 503 (6.7%) 1.43 (1.06-1.93) 
Restricting to ADHD cases with a fixed observation time of 10 years after age 13, i.e. restricting to the 
oldest ADHD cases with at least 10 years of follow up and ignoring SUD diagnoses after age 23  
5 687 1 427 (25.1%) 1.31 (1.08-1.58) 
Abbreviations: ADHD: attention-deficit/hyperactivity disorder. PRS: polygenic risk score. SUD: substance use disorder. OR: odds ratio. CI: confidence interval. PGC: Psychiatric 
Genomics Consortium. 
€ Adjusted for observation time, sex, age and calendar year at first ADHD diagnosis, and the first four principal components to adjust for remaining population stratification. The estimates 
for the polygenic risk score (PRS-ADHD) correspond to a comparison of the highest vs lowest decile of PRS for ADHD. 
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